StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Monday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of ENZ opened at $0.60 on Monday. The business has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $1.01. Enzo Biochem has a 52 week low of $0.59 and a 52 week high of $1.40.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Hedge Funds Weigh In On Enzo Biochem

An institutional investor recently bought a new position in Enzo Biochem stock. BBR Partners LLC acquired a new position in Enzo Biochem, Inc. (NYSE:ENZ) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 100,000 shares of the medical research company’s stock, valued at approximately $112,000. BBR Partners LLC owned 0.19% of Enzo Biochem as of its most recent SEC filing. 36.90% of the stock is currently owned by institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.